Search Results - "RANGWALA, Fatima"

Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1 by Prada, Carlos E., MD, Rangwala, Fatima A., MD, Martin, Lisa J., PhD, Lovell, Anne M., MSN, CNP, Saal, Howard M., MD, Schorry, Elizabeth K., MD, Hopkin, Robert J., MD

“…Objective To characterize morbidity, mortality, and surgical outcomes in pediatric patients with symptomatic plexiform neurofibromas (PNFs). Study design We…”
Get full text

Increased production of sonic hedgehog by ballooned hepatocytes by Rangwala, Fatima, Guy, Cynthia D, Lu, Jiuyi, Suzuki, Ayako, Burchette, James L, Abdelmalek, Manal F, Chen, Wei, Diehl, Anna Mae

“…Ballooned hepatocytes distinguish non‐alcoholic steatohepatitis (NASH) from steatosis. Such cells contain dilated endoplasmic reticulum and ubiquitin…”
Get full text

Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer by Philips, George M, Chan, Isaac S, Swiderska, Marzena, Schroder, Vanessa T, Guy, Cynthia, Karaca, Gamze F, Moylan, Cynthia, Venkatraman, Talaignair, Feuerlein, Sebastian, Syn, Wing-Kin, Jung, Youngmi, Witek, Rafal P, Choi, Steve, Michelotti, Gregory A, Rangwala, Fatima, Merkle, Elmar, Lascola, Christopher, Diehl, Anna Mae

“…Chronic fibrosing liver injury is a major risk factor for hepatocarcinogenesis in humans. Mice with targeted deletion of Mdr2 (the murine ortholog of MDR3)…”
Get full text

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer by Strickler, John H, Rushing, Christel N, Niedzwiecki, Donna, McLeod, Abigail, Altomare, Ivy, Uronis, Hope E, Hsu, S David, Zafar, S Yousuf, Morse, Michael A, Chang, David Z, Wells, James L, Blackwell, Kimberly L, Marcom, P Kelly, Arrowood, Christy, Bolch, Emily, Haley, Sherri, Rangwala, Fatima A, Hatch, Ace J, Nixon, Andrew B, Hurwitz, Herbert I

“…Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical…”
Get full text

3 Development of an integrated method to quantify receptor occupancy for agonist immunotherapeutics that stimulate target cells to migrate from the peripheral blood by Gonzalez, Louis, Ma, Bo, Hernandez, Robert, McKay, Hannah, Rangwala, Fatima, Pandite, Lini, Schreiber, Taylor

“…BackgroundOne of the pharmacodynamic measures of biologic compounds is an assessment of target receptor/ligand occupancy (RO). If the primary mechanism for…”
Get full text

Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues by MILLER, Shyra J, RANGWALA, Fatima, MAUTNER, Victor, UPADHYAYA, Meena, MUIR, David, WALLACE, Margaret, HAGEN, Jussara, QUELLE, Dawn E, WATSON, Mark A, PERRY, Arie, GUTMANN, David H, RATNER, Nancy, WILLIAMS, Jon, ACKERMAN, Peter, KONG, Sue, JEGGA, Anil G, KAISER, Sergio, ARONOW, Bruce J, FRAHM, Silke, KLUWE, Lan

“…Malignant peripheral nerve sheath tumors (MPNST) are highly invasive soft tissue sarcomas that arise within the peripheral nerve and frequently metastasize. To…”
Get full text

494 Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas by Johnson, Melissa, Siu, Lilian, Hong, David, Schoffski, Patrick, Galvao, Vladimir, Rangwala, Fatima, Hernandez, Robert, Gonzalez, Louis, Ma, Bo, Pandite, Lini, Brana, Irene

“…BackgroundPD1-Fc-OX40L, is a hexameric, bi-functional fusion protein with an extracellular domain (ECD) of PD-1 (70 pM affinity to PD-L1) linked to the ECD of…”
Get full text

Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines by Rangwala, Fatima, Williams, Kevin P, Smith, Ginger R, Thomas, Zainab, Allensworth, Jennifer L, Lyerly, H Kim, Diehl, Anna Mae, Morse, Michael A, Devi, Gayathri R

“…Crosstalk between malignant hepatocytes and the surrounding peritumoral stroma is a key modulator of hepatocarcinogenesis and therapeutic resistance. To…”
Get full text

Cancer Stem Cells: Repair Gone Awry? by Rangwala, Fatima, Omenetti, Alessia, Diehl, Anna Mae

“…Because cell turnover occurs in all adult organs, stem/progenitor cells within the stem-cell niche of each tissue must be appropriately mobilized and…”
Get full text

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer by Subbiah, Vivek, Kreitman, Robert J, Wainberg, Zev A, Cho, Jae Yong, Schellens, Jan H M, Soria, Jean Charles, Wen, Patrick Y, Zielinski, Christoph, Cabanillas, Maria E, Urbanowitz, Gladys, Mookerjee, Bijoyesh, Wang, Dazhe, Rangwala, Fatima, Keam, Bhumsuk

“…Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E-mutated anaplastic…”
Get full text

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer by Lakhani, Nehal J., Stewart, Daphne B., Richardson, Debra L., Dockery, Lauren E., Van Le, Linda, Call, Justin A, Rangwala, Fatima A., Scholl, Anya, Wang, Guanfang, Ma, Bo, Metenou, Simon, Gonzalez, Louis, Pandite, Arundathy, Hamilton, Erika P.

“…5544 Background: SIRPα-Fc-CD40L is a hexameric, bi-functional fusion protein consisting of SIRPα linked to CD40L via an inert Fc linker. This molecule…”
Get full text

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer by Middleton, Gary, Yang, Yiqun, Campbell, Catarina D, André, Thierry, Atreya, Chloe E, Schellens, Jan H M, Yoshino, Takayuki, Bendell, Johanna C, Hollebecque, Antoine, McRee, Autumn J, Siena, Salvatore, Gordon, Michael S, Tabernero, Josep, Yaeger, Rona, O'Dwyer, Peter J, De Vos, Filip, Van Cutsem, Eric, Millholland, John M, Brase, Jan C, Rangwala, Fatima, Gasal, Eduard, Corcoran, Ryan B

“…The influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined…”
Get full text

LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade by Yoo, Kyung Jin, Johannes, Kellsey, González, Louis E., Patel, Arpita, Shuptrine, Casey W., Opheim, Zachary, Lenz, Karen, Campbell, Kristen, Nguyen, Thuy-Ai, Miriyala, Jayalakshmi, Smith, Connor, McGuire, Ashlyn, Tsai, Yi-Hsuan, Rangwala, Fatima, de Silva, Suresh, Schreiber, Taylor H., Fromm, George

“…Coinhibition of TIGIT (T cell immunoreceptor with Ig and ITIM domains) and PD-1/PD-L1 (PD-1/L1) may improve response rates compared with monotherapy PD-1/L1…”
Get full text

Abstract 1697: The development of an in vivo model of checkpoint acquired resistance, reveals a program of interferon hyperstimulation, resulting in dysregulation of MHC class I, protein translation/trafficking, and other unique pathways, that may be useful for guiding clinical strategy in patients with phenotypic similarities by Fromm, George J., Memon, Danish, de Silva, Suresh, Yoo, Kyung Jin, Johannes, Kellsey, Shuptrine, Casey, Miriyala, Jaya, Patel, Arpita, Rangwala, Fatima, Opheim, Zachary, Nguyen, Thuy-Ai, Gonzalez, Louis, Schreiber, Taylor H., Hellmann, Matthew D., Miller, Martin L.

“…Approximately 20-40% of cancer patients who initially benefit from PD-1/L1 checkpoint blockade later develop progressive disease, which is associated with…”
Get full text

Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis by Spiegel, Daphna, Boyer, Matthew, Hong, Julian C., Williams, Christina D., Kelley, Michael J., Rangwala, Fatima A., Salama, Joseph Kamel, Palta, Manisha

“…Abstract only 741 Background: Adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME) for locoregionally advanced rectal…”
Get full text

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL) by Kreitman, Robert J., Moreau, Philippe, Hutchings, Martin, Gazzah, Anas, Blay, Jean-Yves, Wainberg, Zev A., Stein, Alexander, Dietrich, Sascha, de Jonge, Maja J.A., Willenbacher, Wolfgang, De Greve, Jacques, Arons, Evgeny, Ravandi, Farhad, Rangwala, Fatima, Burgess, Paul, Mookerjee, Bijoyesh, Subbiah, Vivek

“…Hairy cell leukemia is a rare, indolent, B-cell lymphoproliferative disease characterized by the BRAF V600E mutation in 90% to 100% of patients. Few treatment…”
Get full text

Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC) by Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Cho, Jae Yong, Schellens, Jan H.M., Soria, Jean-Charles, Wen, Patrick Y., Zielinski, Christoph, Urbanowitz, Gladys, Mookerjee, Bijoyesh, Wang, Dazhe, Rangwala, Fatima A., Keam, Bhumsuk

“…Abstract only 6023 Background: ATC is a rare, aggressive malignancy with a dismal prognosis. Median overall survival (OS) is < 6 mo. Combined BRAF and MEK…”
Get full text

RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG) by Wen, Patrick, De Greve, Jacques, Mason, Warren, Hofheinz, Ralf-Dieter, Dietrich, Sascha, de Vos, Filip, van den Bent, Martin, Mookerjee, Bijoyesh, Boran, Aislyn, Burgess, Paul, Rangwala, Fatima, Gazzah, Anas

“…Abstract BACKGROUND Approximately 9%-18% of LGGs possess BRAF V600E mutations. Combined BRAF and MEK inhibition is efficacious in BRAF V600–mutated melanoma,…”
Get full text

RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) by Wen, Patrick, Alexander, Stein, Yung-Jue, Bang, van den Bent, Martin, Gazzah, Anas, Dietrich, Sascha, de Vos, Filip, van Linde, Mayra, Lai, Albert, Chi, Andrew, Prager, Gerald, Campone, Mario, von Bubnoff, Nikolas, Fasolo, Angelica, Lopez-Martin, Jose, Mookerjee, Bijoyesh, Boran, Aislyn, Burgess, Paul, Rangwala, Fatima, Subbiah, Vivek

“…Abstract BACKGROUND Current treatment outcomes for patients with recurrent HGG are poor, with median progression-free survival (PFS) and overall survival (OS)…”
Get full text

ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy by Subbiah, Vivek, Bang, Yung-Jue, Lassen, Ulrik Niels, Wainberg, Zev A., Soria, Jean-Charles, Wen, Patrick Y., Zenz, Thorsten, Moreau, Philippe, Brunsvig, Paal, De Braud, Filippo G., De Greve, Jacques, De Jonge, Maja J., Hofheinz, Ralf D., Italiano, Antoine, Stein, Alexander, Willenbacher, Wolfgang, Schellens, Jan H.M., Zielinski, Christoph, Rangwala, Fatima A., Kreitman, Robert J.

“…Abstract only…”
Get full text